What this is
- How it works
- A cell therapy: living cells given to the patient as the treatment.-cel: cell therapies WHO name stem
- How it’s given
- “Peripheral infusion of 150 million allogeneic cardiosphere-derived cells administered every three months”In the company’s words, NCT04428476 on ClinicalTrials.gov
- Tested for
- Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases and 1 more
- Main trialPhase 3
- “HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called deramiocel (CAP-1002) in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either deramiocel or placebo every 3 months for a total of 4 doses during the first 12 months of the study. All participants will be eligible to receive 4 doses of deramiocel for an additional…”In the company’s words, NCT05126758 on ClinicalTrials.gov
- Other names
- Allogeneic Cardiosphere-Derived Cells · CAP-1002 · CDCs · Cardiosphere-Derived Cells
Other drugs for Muscular Dystrophies
- TideglusibAMO Pharma Limited · Phase 2/3
- AOC 1044Avidity Biosciences, Inc. · Phase 3
- Mexiletine granulesLupin Ltd. · Phase 3
- BBP-418ML Bio Solutions, Inc. · Phase 3
- Givinostat HydrochlorideItalfarmaco · Phase 3
- AOC-1020Avidity Biosciences, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 18 Jun 2025 | A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | |
| Phase 2Active, not recruiting | 16 Feb 2022 | Open-label Extension of the HOPE-2 Trial | |
| Phase 2Completed | 14 Sep 2017 | HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) | |
| Phase 2Completed | 6 Mar 2019 | Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE) | |
| Phase 2Completed | 10 Mar 2020 | A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | |
| Phase 2Completed | 4 Feb 2022 | Intravenous Infusion of CAP-1002 in Patients With COVID-19 | |
| Phase 1/2Terminated | 3 Jul 2017 | Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026